DiaGenic ASA Provides Update on Its Financing Process

Published: Sep 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic ASA (OSE:DIAG): Based inter alia on the announced negative results of the validation study for MCItect®, and further to the announced cost reduction programme for DiaGenic ASA (the “Company”), the board of directors has decided to intensify the efforts to obtain equity financing, or facilitate an asset or trade sale. The Company has appointed DNB Markets to assist in this process (contact details below). If a solution for the Company’s working capital requirement is not identified in the near future, the board of directors will evaluate the financial basis for the Company’s future operations.

Help employers find you! Check out all the jobs and post your resume.

Back to news